Chad is 37 years old. He’s a husband, a father, a brother, and a friend. He’s strong, hardworking, and the steady presence our family leans on. And now, once again, he’s facing the fight of his life.

At 33, just before his 34th birthday, Chad was diagnosed with a rare and aggressive cancer: high-grade myxoid liposarcoma. The cancer began in his leg, and what followed was a long and difficult battle. Chad underwent surgery to remove the tumor, completed 25 rounds of radiation, endured another surgery, and went through 5 rounds of intensive AIM chemotherapy. It was physically and emotionally exhausting, but Chad faced each step with determination and courage.

Eventually, we received the words we had been hoping for — remission.

Our family exhaled. We slowly began rebuilding, finding a sense of normal again, and allowing ourselves to hope for the future.

Because of the aggressive nature of Chad’s cancer, he continued routine surveillance scans to carefully monitor for recurrence. During his most recent scan, without warning and without symptoms, our world shattered again. The scans revealed that Chad’s cancer has returned.

Chad is now preparing to begin another aggressive treatment plan. This news came just before his 37th birthday — a time that should have been filled with celebration, not fear and uncertainty.

But if you know Chad, you know he is not someone who backs down. He has already faced this battle once, and he is preparing to fight again with strength, determination, and hope. Through every challenge, Chad remains focused on what matters most — his family, his future, and continuing to live life with courage.

Chad has already proven how strong he is. And now, once again, he’s stepping into the fight with everything he has.

Thanks to the Race to Cure Sarcoma events, SFA has invested over $20 million in sarcoma research, funding over 200 grants in 12 countries leading to close to 200 total publications, adding to the sarcoma research discourse. This has led to $26 million+ in additional funding, 10+ clinical trials with 5 additional pending, and 2 patents. Your investment in the RTCS events, is an investment in saving lives.